Floatz logo

Dostarlimab

Vagina Neoplasm

Yonsei Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Vagina Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
Yonsei University
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Fludarabine
HRYZ Biotech Co.
Phase 1CC
Hryz-T101 Tcr-T Cell
HRYZ Biotech Co.
Phase 1CC
Cyclophosphamide
HRYZ Biotech Co.
Phase 1CC

Same molecule, other indications

Dostarlimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Neoplasms, ColonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →